Christopher Rawlinson’s Post

Our blood diagnostics are the cornerstone of modern hematology, setting new standards in healthcare precision. Learn why you should choose North West Labs for blood testing at https://lnkd.in/gdUisHXc. 🩸 #NorthWestLabs #NWLabs #Lab #LabTesting #BloodTesting #BloodDiagnostics

RPT: Battles of the Alphas Breakthrough Therapy Designation is based on the results from phase 1 and the ongoing phase 2 clinical trials that assessed the safety and efficacy of AlphaMedixTM. In the phase 1 study, treatment was well-tolerated, with a response rate (ORR according to RECIST 1.1) of 62.5% for the GEP-NET patients who had never received PRRT with LutatheraTM, which is based on the beta-particle emitter Lutetium-177. In the phase 2 trial, the target response rate has already been achieved ahead of top-line data, expected in mid-2024.

New TSD on treatment switching! NICE's Decision Support Unit has published a new technical support document, written by Helen Bell Gorrod, Keith R Abrams and I. TSD 24 is an update to TSD 16 and is about treatment switching in randomised controlled trials - including trial design, what to adjust for, how, and reporting guidelines. Treatment switching happens in a lot of oncology trials, and sometimes it means that a standard intention-to-treat analysis doesn't address the decision problem we're interested in. NICE has been open to statistical analyses that adjust for treatment switching for a long time, but these won't be accepted if they are not well justified or are badly carried out. One of the big problems is that evidence submissions often don't adequately explain what has been done and why, and to address this TSD 24 offers comprehensive reporting guidelines. Analyses that are well described are much more likely to be accepted by decision-makers! https://lnkd.in/eGecTHvE

🔬 Exciting Updates in Clinical Trials! 🔬 🔹 Viridian Strive clinical trial is currently seeking Thyroid Eye Disease (TED) adult subjects! Eligible individuals can refer via the chat function on CockerhamMD.com for an intravenous dose of either 3 or 10 mg. Notably, there is no placebo arm for this trial. 🔹 Horizon/Amgen has successfully recruited their first subject for a clinical trial focusing on the transcutaneous delivery of a modified Tepezza molecule. The randomized process for this study is set to commence on July 9th. 🔹 In another recent development, the Genentech/Roche clinical trial is now live, with a primary focus on evaluating the efficacy of an IL6 monoclonal antibody. Stay tuned for more updates on these groundbreaking clinical trials! 🌟 #ClinicalTrials #Healthcare #MedicalResearch

Our abstract was selected for presentation in a poster session at the Triple Meeting (EORTC-NCI-AACR)! Preliminary safety, pharmacokinetic profiles, and clinical activity as monotherapy for TT125-802 will be presented. TT125-802 is a highly selective, BET-sparing bromodomain inhibitor of the transcriptional co-activators CBP/p300. TT125-802 has an encouraging safety profile without hematological toxicities. TT125-802 has demonstrated clinical monotherapy activity in several relevant tumor types including a confirmed and lasting response in EGFRmut NSCLC. Check out our poster (abstract #121; poster board PB109) today between 12.00 and 19.00. #enasymp24

In this month's Science Spotlight, a team from Germany validated the TruSight Oncology 500 ctDNA assay using reference and patient samples, including Seraseq® ctDNA Reference Material v2 AF1% and Seraseq® ctDNA Reference Material v2 AF0.5%. They demonstrated high sensitivity and low variant detection variability of the assay for SNVs, insertions, deletions and fusions down to a VAF of 0.5% in the reference samples, and the VAFs were concordant with previous dPCR results in patient samples. Interestingly, the sensitivity and variability were dependent on the reference material used, with the Seraseq® ctDNA reference materials resulting in much lower variability and better reported sensitivity. Read the full article here to learn more about their findings! https://hubs.ly/Q02plqvh0 #ScienceSpotlight

NEW from #ASH2023 | RUBY & EdiTHAL trials: evaluating the safety and efficacy of EDIT-301 in SCD & #thalassemia 🎥 🩸 Rabi Hanna, MD, Cleveland Clinic, shares insights into the RUBY and EdiTHAL trials (NCT04853576; NCT05444894), which are evaluating the safety and efficacy of EDIT-301, a novel investigational #gene-edited #autologous product, in patients with #sicklecelldisease (SCD) and #transfusion-dependent #betathalassemia 🔦 In both trials, EDIT-301 has demonstrated promising safety and tolerability, with no severe adverse events (AEs) observed so far 🌟 Give it a watch to learn more 👉 https://lnkd.in/dUN5rsVW #HemOnc American Society of Hematology #Leusm

On World Cancer Day, we are all reminded of the bravery of our most critical patients and how crucial it is to provide the best healthcare possible for patients everywhere. At Sysmex, we are dedicated to developing innovative analyzers to help clinical labs provide accurate results regardless of the diagnosis. White Precursor Cell (WPC) testing on the XN-20™ hematology module offers automated, next-level analysis of white blood cells, giving highly skilled laboratory scientists sensitive and specific flagging for the crucial identification of abnormal cells. Efficiency can be gained when WPC testing is reflexed using the XN analyzer’s onboard rules or Caresphere™ Workflow Solution (WS). For more information on how Sysmex can help your laboratory help provide diagnostic testing for critical patients, contact your Sysmex Sales Representative or visit https://ow.ly/nYb450QxtNh. *XN analyzers are FDA-cleared to classify and count blood cells. #WorldCancerDay #Sysmex #Hematology #TogetherForABetterHealthcareJourney

Sharing an in-depth look at the “radiopharma” competitive landscape, courtesy of OPCO. Dive into the latest insights on this potentially impactful modality that is poised to change the standard of care in oncology! #biotech #healthcare #medicine #radiopharma #oncology #cancer

NONCLINICAL PROGRAM POC Rodent Studies of PK, Efficacy, and Tolerability of Continuous LLD. From 2 minutes - iPRECIO Programmable Pump use. Now in Clinical Trials https://lnkd.in/gwy7MXhq #drugdelivery #continousinfusion #multiplemyeloma #lenalidomide https://lnkd.in/gf2VrYG6